FR20C1030I2 - Inhibiteurs de beta-lactamase - Google Patents

Inhibiteurs de beta-lactamase

Info

Publication number
FR20C1030I2
FR20C1030I2 FR20C1030C FR20C1030C FR20C1030I2 FR 20C1030 I2 FR20C1030 I2 FR 20C1030I2 FR 20C1030 C FR20C1030 C FR 20C1030C FR 20C1030 C FR20C1030 C FR 20C1030C FR 20C1030 I2 FR20C1030 I2 FR 20C1030I2
Authority
FR
France
Prior art keywords
beta
lactamase inhibitors
lactamase
inhibitors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR20C1030C
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Merck Sharp and Dohme LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Publication of FR20C1030I1 publication Critical patent/FR20C1030I1/fr
Application filed by Merck Sharp and Dohme LLC filed Critical Merck Sharp and Dohme LLC
Application granted granted Critical
Publication of FR20C1030I2 publication Critical patent/FR20C1030I2/fr
Active legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C07D211/58—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D211/78—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pyrrole Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
FR20C1030C 2008-01-18 2020-07-10 Inhibiteurs de beta-lactamase Active FR20C1030I2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1153308P 2008-01-18 2008-01-18
PCT/US2009/031047 WO2009091856A2 (fr) 2008-01-18 2009-01-15 Inhibiteurs de bêta-lactamase

Publications (2)

Publication Number Publication Date
FR20C1030I1 FR20C1030I1 (fr) 2020-02-10
FR20C1030I2 true FR20C1030I2 (fr) 2021-08-27

Family

ID=40642204

Family Applications (3)

Application Number Title Priority Date Filing Date
FR20C1032C Active FR20C1032I2 (fr) 2008-01-18 2020-07-10 Inhibiteurs de beta-lactamase
FR20C1031C Active FR20C1031I2 (fr) 2008-01-18 2020-07-10 Inhibiteurs de beta-lactamase
FR20C1030C Active FR20C1030I2 (fr) 2008-01-18 2020-07-10 Inhibiteurs de beta-lactamase

Family Applications Before (2)

Application Number Title Priority Date Filing Date
FR20C1032C Active FR20C1032I2 (fr) 2008-01-18 2020-07-10 Inhibiteurs de beta-lactamase
FR20C1031C Active FR20C1031I2 (fr) 2008-01-18 2020-07-10 Inhibiteurs de beta-lactamase

Country Status (39)

Country Link
US (2) US8487093B2 (fr)
EP (2) EP2231667B1 (fr)
JP (3) JP5038509B2 (fr)
KR (2) KR101800610B1 (fr)
CN (2) CN101918407B (fr)
AU (1) AU2009206119C1 (fr)
BR (1) BRPI0906871B1 (fr)
CA (1) CA2712783C (fr)
CO (1) CO6331438A2 (fr)
CR (1) CR11626A (fr)
CY (5) CY1114900T1 (fr)
DK (2) DK2231667T3 (fr)
DO (1) DOP2010000218A (fr)
EC (2) ECSP10010345A (fr)
ES (2) ES2533826T3 (fr)
FR (3) FR20C1032I2 (fr)
HK (2) HK1143809A1 (fr)
HN (1) HN2010001395A (fr)
HR (2) HRP20131123T1 (fr)
HU (2) HUS2000023I1 (fr)
IL (1) IL206395A (fr)
LT (3) LTPA2020517I1 (fr)
LU (1) LUC00165I2 (fr)
MA (1) MA32025B1 (fr)
ME (1) ME02089B (fr)
MX (1) MX2010007823A (fr)
MY (1) MY162532A (fr)
NI (1) NI201000115A (fr)
NL (2) NL301051I2 (fr)
NO (3) NO2020023I1 (fr)
NZ (1) NZ586861A (fr)
PL (2) PL2666774T3 (fr)
PT (2) PT2231667E (fr)
RS (2) RS53052B (fr)
RU (1) RU2445314C9 (fr)
SI (2) SI2666774T1 (fr)
UA (1) UA101966C2 (fr)
WO (1) WO2009091856A2 (fr)
ZA (1) ZA201005333B (fr)

Families Citing this family (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS53052B (en) * 2008-01-18 2014-04-30 Merck Sharp & Dohme Corp. INHIBITOR BETA-LACTAMASE
DK2603514T3 (en) 2010-08-10 2018-10-29 Rempex Pharmaceuticals Inc Cyclic boronic ester derivatives and their therapeutic uses
CN104892490B (zh) * 2010-12-22 2017-07-21 明治制果药业株式会社 用于制备光学活性二氮杂环辛烷衍生物的中间体化合物的化合物
US8772490B2 (en) * 2010-12-22 2014-07-08 Meiji Seika Pharma Co., Ltd. Optically active diazabicyclooctane derivatives and process for preparing the same
CA2780403C (fr) * 2011-06-17 2020-04-21 Forest Laboratories Holdings Ltd. Procedes de preparation de composes heterocycliques, y compris le trans-7-oxo-6-(sulfoxy)-1,6-diazabicyclo¬3,2,1|octane-2-carboxamide et ses sels
PL2748165T3 (pl) * 2011-08-27 2017-05-31 Wockhardt Limited Pochodne 1,6-diazabicyklo[3,2,1]oktan-7-onu i ich zastosowanie w leczeniu zakażeń bakteryjnych
BR112013032974A2 (pt) 2011-08-30 2016-09-06 Wockhardt Ltd "derivados de 1,6-diazabiciclo [3,2,1]-octan-7-ona, seus usos, e composições farmacêuticas".
US9012491B2 (en) 2011-08-31 2015-04-21 Rempex Pharmaceuticals, Inc. Heterocyclic boronic acid ester derivatives and therapeutic uses thereof
US8796257B2 (en) 2011-12-02 2014-08-05 Naeja Pharmaceutical Inc. Bicyclic compounds and their use as antibacterial agents and β-lactamase inhibitors
US9505761B2 (en) 2011-12-02 2016-11-29 Fedora Pharmaceuticals Inc. Bicyclic compounds and their use as antibacterial agents and beta-lactamase inhibitors
BR112014016804A8 (pt) 2012-01-06 2017-07-04 Univ California composições, métodos de uso e métodos de tratamento
EP2831069B1 (fr) 2012-03-30 2017-07-12 Merck Sharp & Dohme Corp. Inhibiteurs des beta-lactamases dérivés d'isoxazole
US8933232B2 (en) * 2012-03-30 2015-01-13 Cubist Pharmaceuticals, Inc. 1,3,4-oxadiazole and 1,3,4-thiadiazole beta-lactamase inhibitors
US8969570B2 (en) * 2012-03-30 2015-03-03 Cubist Pharmaceuticals, Inc. Beta-lactamase inhibitors
US8916709B2 (en) 2012-03-30 2014-12-23 Cubist Pharmaceuticals, Inc. 1,2,4-oxadiazole and 1,2,4-thiadiazole β-lactamase inhibitors
AR090539A1 (es) 2012-04-02 2014-11-19 Astrazeneca Ab COMPUESTOS INHIBIDORES DE b LACTAMASA
EP2847327B1 (fr) 2012-05-08 2018-12-26 Codexis, Inc. Biocatalyseurs et procédés pour l'hydroxylation de composés chimiques
US9156858B2 (en) 2012-05-23 2015-10-13 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
SI2857401T1 (sl) 2012-05-30 2020-01-31 Meiji Seika Pharma Co., Ltd. Novi inhibitor beta-laktamaze in metoda za proizvajanje le-tega
US10561675B2 (en) 2012-06-06 2020-02-18 Rempex Pharmaceuticals, Inc. Cyclic boronic acid ester derivatives and therapeutic uses thereof
CA2881169C (fr) 2012-08-25 2020-06-16 Wockhardt Limited Derives de 1,6-diazabicyclo[3,2,1]octan-7-one et leur utilisation dans le traitement d'infections bacteriennes
WO2014069351A1 (fr) 2012-11-01 2014-05-08 株式会社カネカ Procédé pour la production d'un composé d'urée bicyclique optiquement actif
CA2893943C (fr) 2012-12-07 2021-03-02 VenatoRx Pharmaceuticals, Inc. Inhibiteurs de beta-lactamase
UA111925C2 (uk) 2012-12-11 2016-06-24 Федора Фармасьютікалз Інк. БІЦИКЛІЧНІ СПОЛУКИ ТА ЇХ ВИКОРИСТАННЯ ЯК АНТИБАКТЕРІАЛЬНИХ АГЕНТІВ ТА ІНГІБІТОРІВ β-ЛАКТАМАЗИ
US9241947B2 (en) 2013-01-04 2016-01-26 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
EP2941247A4 (fr) 2013-01-04 2017-02-08 Rempex Pharmaceuticals, Inc. Dérivés d'acide boronique et leurs utilisations thérapeutiques
US9101638B2 (en) 2013-01-04 2015-08-11 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
CN104994844A (zh) 2013-01-04 2015-10-21 莱姆派克斯制药公司 硼酸衍生物及其治疗用途
CN105101970B (zh) 2013-01-10 2018-11-20 维纳拓尔斯制药公司 β-内酰胺酶抑制剂
KR101774132B1 (ko) 2013-03-08 2017-09-01 욱크하르트 리미티드 (2s, 5r)-7-옥소-6-술포옥시-2-[((3r)-피페리딘-3-카보닐)-히드라지노 카보닐]-1,6-디아자-비사이클로[3.2.1]-옥탄의 제조 방법
CN105143226A (zh) * 2013-03-08 2015-12-09 沃克哈特有限公司 制备(2s,5r)-2-甲酰胺基-7-氧代-6-磺酰氧基-1,6-二氮杂-双环[3.2.1]辛烷的钠盐的方法
CA2904079C (fr) 2013-03-08 2017-09-19 Wockhardt Limited Procede pour la preparation du (2s,5r)-7-oxo-6-sulfo-oxy-2-[((3r)-piperidine-3-carbonyl)-hydrazino carbonyl]-1,6-diaza-bicyclo-[3.2.1]-octane
WO2014135931A1 (fr) * 2013-03-08 2014-09-12 Wockhardt Limited Procédé pour la préparation du (2s, 5r)-7-oxo-6-sulfo-oxy-2-[((3r)-pipéridine-3-carbonyl)-hydrazino carbonyl]-1,6-diaza-bicyclo[3.2.1]octane
BR112015021186A2 (pt) * 2013-03-08 2017-07-18 Wockhardt Ltd processo para a preparação de (2s,5r)-7-oxo-6-sulfóxi-2-[((3r)-pirrolidina-3-carbonil)-hidrazino carbonil]-1,6-diaza-biciclo[3.2.1]octano
MX2015011720A (es) * 2013-03-08 2015-12-01 Wockhardt Ltd Proceso para la preparcion de monoacido de (2s,5r)-{[(4-aminopiper idin-4-il)carbonil]-7-oxo-1,6-diaza-biciclo[3.2.1 oct-6-il} ester sulfurico.
EP2970340B1 (fr) 2013-03-14 2020-02-12 Venatorx Pharmaceuticals, Inc. Inhibiteurs de bêta-lactamase
US9120795B2 (en) 2013-03-14 2015-09-01 Cubist Pharmaceuticals, Inc. Crystalline form of a β-lactamase inhibitor
AU2014278556B2 (en) * 2013-06-10 2018-07-19 Merck Sharp & Dohme Llc Preparation of tert-butyl 4-((1R,2S,5R)-6- (benzyloxy)-7-oxo-1,6-diazabicyclo[3.2.1]octane-2- carboxamido)piperidine-1-carboxylate
AR097744A1 (es) 2013-09-24 2016-04-13 Meiji Seika Pharma Co Ltd Proceso para producir derivado de diazabiciclooctano y su intermediario
US9120796B2 (en) 2013-10-02 2015-09-01 Cubist Pharmaceuticals, Inc. B-lactamase inhibitor picoline salt
NZ719568A (en) 2013-10-08 2018-06-29 Meiji Seika Pharma Co Ltd Crystals of diazabicyclooctane derivative and production method for crystals of diazabicyclooctane derivative
US9604986B2 (en) 2013-11-26 2017-03-28 Wockhardt Limited Polymorphs and process for preparation of (2S, 5R)-7-oxo-N-[(2S)-pyrrolidin-2-yl-methyloxy]-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide
AU2015236369B2 (en) 2014-03-24 2017-02-16 Novartis Ag Monobactam organic compounds for the treatment of bacterial infections
WO2015150890A1 (fr) * 2014-03-29 2015-10-08 Wockhardt Limited Procédé de préparation de mono-{2-(5-(3-amino-propyl)-[1,3,4]oxadiazol-2-yl]-7-oxo-1,6-diazabicyclo[3.2.1]oct-6-yl}ester d'acide sulfurique trans
IN2014MU01195A (fr) * 2014-03-29 2015-10-02 Wockhardt Ltd
EP3139930B1 (fr) 2014-05-05 2024-08-14 Melinta Therapeutics, Inc. Sels et polymorphes de dérivés cycliques d'ester d'acide boronique, et leurs utilisations thérapeutiques
WO2015171430A1 (fr) 2014-05-05 2015-11-12 Rempex Pharmaceuticals, Inc. Synthèse de sels boronate et utilisations de ceux-ci
MX2016015093A (es) 2014-05-19 2017-03-27 Rempex Pharmaceuticals Inc Derivados de acido boronico y sus usos terapeuticos.
EP3882252A1 (fr) 2014-06-11 2021-09-22 Venatorx Pharmaceuticals, Inc. Inhibiteurs de bêta-lactamase
US9511142B2 (en) 2014-06-11 2016-12-06 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors
AU2015284307A1 (en) 2014-07-01 2017-02-02 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
BR112017010132B1 (pt) * 2014-11-17 2023-02-14 Entasis Therapeutics Limited Combinações e seus usos no tratamento de infecções bacterianas resistentes
US10662205B2 (en) 2014-11-18 2020-05-26 Qpex Biopharma, Inc. Cyclic boronic acid ester derivatives and therapeutic uses thereof
CN107428784B (zh) 2014-12-02 2020-08-21 默沙东公司 用于制备4-((2s,5r)-6-(苄基氧基)-7-氧代-1,6-二氮杂双环[3.2.1]辛烷-2-甲酰胺基)哌啶-1-甲酸叔丁酯及其类似物的方法
ES2821826T3 (es) 2014-12-05 2021-04-27 Meiji Seika Pharma Co Ltd Método para producir cristales de derivado de diazabiciclooctano y preparación liofilizada estable
US20180051041A1 (en) 2015-03-17 2018-02-22 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
RU2715058C2 (ru) 2015-03-31 2020-02-25 Мутабилис Гетероциклические соединения и их применение для предупреждения или лечения бактериальных инфекций
MX2017014080A (es) * 2015-05-07 2018-07-06 Mutabilis Compuestos heterociclicos y su uso en la prevencion o tratamiento de las infecciones bacterianas.
CN108472284A (zh) 2015-09-11 2018-08-31 维纳拓尔斯制药公司 β-内酰胺酶抑制剂
MX2017013792A (es) * 2015-09-16 2018-07-06 Xuanzhu Pharma Co Ltd INHIBIDORES DE íŸ-LACTAMASA Y USOS DE LOS MISMOS.
AU2016332964A1 (en) 2015-10-02 2018-04-12 Legochem Biosciences, Inc. Compositions and methods for inhibiting beta-lactamase
WO2017100537A1 (fr) 2015-12-10 2017-06-15 VenatoRx Pharmaceuticals, Inc. Inhibiteurs de bêta-lactamases
EP3386982A1 (fr) * 2015-12-11 2018-10-17 The Wockhardt Limited Composés contenant du 7-oxo-6-(sulfo-oxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide et leur utilisation dans le traitement d'infections bactériennes
US10472345B2 (en) 2016-02-04 2019-11-12 Merck Sharp & Dohme Corp. Methods of preparing hydroxylamine derivatives useful in the preparation of anti-infective agents
CN108778270B (zh) * 2016-03-31 2021-07-30 吉林四环制药有限公司 一种抗菌组合物及其用途
US10184117B2 (en) 2016-06-09 2019-01-22 Codexis, Inc. Biocatalysts and methods for hydroxylation of chemical compounds
PT3478693T (pt) 2016-06-30 2021-10-25 Qpex Biopharma Inc Derivados de ácido borónico e suas utilizações terapêuticas
WO2018027062A1 (fr) 2016-08-04 2018-02-08 VenatoRx Pharmaceuticals, Inc. Composés contenant du bore
PL3512851T3 (pl) * 2016-09-16 2022-11-14 Entasis Therapeutics Limited Związki stanowiące inhibitory beta-laktamazy
WO2018053057A2 (fr) * 2016-09-19 2018-03-22 Merck Sharp & Dohme Corp. Procédé de préparation d'intermédiaires d'hydroxyurée inhibiteurs des bêta-lactamases
JOP20190061A1 (ar) * 2016-09-28 2019-03-26 Novartis Ag مثبطات بيتا-لاكتاماز
CN108078982B (zh) * 2016-11-21 2020-02-07 天津大学 脯氨酸衍生物在制备β-内酰胺酶抑制剂中的用途
CN110678186A (zh) 2017-03-06 2020-01-10 维纳拓尔斯制药公司 包含β-内酰胺酶抑制剂的固体形式和组合式组合物及其用途
CN108619141B (zh) * 2017-03-16 2021-09-10 山东轩竹医药科技有限公司 一种抗菌组合物及其用途
HUE057592T2 (hu) 2017-05-08 2022-05-28 Entasis Therapeutics Inc Vegyületek és eljárások bakteriális fertõzések kezelésére
US10085999B1 (en) * 2017-05-10 2018-10-02 Arixa Pharmaceuticals, Inc. Beta-lactamase inhibitors and uses thereof
WO2018218190A1 (fr) 2017-05-26 2018-11-29 VenatoRx Pharmaceuticals, Inc. Inhibiteurs de protéines de liaison à la pénicilline
US11267826B2 (en) 2017-05-26 2022-03-08 VenatoRx Pharmaceuticals, Inc. Penicillin-binding protein inhibitors
US11299467B2 (en) 2017-07-21 2022-04-12 Antabio Sas Chemical compounds
CN109568323B (zh) * 2017-09-29 2022-09-30 吉林四环制药有限公司 抗菌组合物及其用途
CA3078627A1 (fr) 2017-10-11 2019-04-18 Qpex Biopharma, Inc. Derives d'acide boronique et synthese de ces derniers
EP3719020B1 (fr) 2017-12-01 2022-09-21 Qilu Pharmaceutical Co., Ltd. Forme cristalline d'un inhibiteur de beta-lactamase et son procédé de préparation
CN109956941B (zh) * 2017-12-25 2020-08-04 新发药业有限公司 一种阿维巴坦的简便制备方法
CA3089150A1 (fr) 2018-01-25 2019-01-24 Suzhou Sinovent Pharmaceuticals Co., Ltd. Nhibiteurs de beta-lactamase et leur utilisation
EP3781576B1 (fr) 2018-04-20 2024-06-12 Qpex Biopharma, Inc. Dérivés d'acide boronique et leurs utilisations thérapeutiques
EP3572411A1 (fr) 2018-05-21 2019-11-27 Antabio SAS Dérivés de thiazole comme inhibiteurs de métallo-bêta-lactamases
EP3670512A1 (fr) * 2018-12-18 2020-06-24 Antabio SAS Diazabicyclooctanones comme inhibiteurs de sérine beta-lactamases
US11905286B2 (en) 2018-08-09 2024-02-20 Antabio Sas Diazabicyclooctanones as inhibitors of serine beta-lactamases
LT3833665T (lt) * 2018-08-09 2023-11-10 Antabio Sas Diazabiciklooktanonai kaip serino beta-laktamazės inhibitoriai
CA3113606A1 (fr) * 2018-09-21 2020-03-26 Api Corporation Procede de production de derives d'acide amine
JP7437847B2 (ja) * 2018-10-01 2024-02-26 アリクサ ファーマシューティカルズ、インコーポレイテッド レレバクタムの誘導体およびその使用
CN111072660B (zh) * 2018-10-22 2021-05-18 新发药业有限公司 一种瑞来巴坦的简便制备方法
AU2020237440B2 (en) 2019-03-12 2022-10-20 Arixa Pharmaceuticals, Inc. Crystalline form of an avibactam derivative
EP3959205A4 (fr) * 2019-04-26 2023-05-17 Merck Sharp & Dohme LLC Procédé de préparation d'intermédiaires utiles pour la fabrication de (2s,5r)-7-oxo-n-pipéridin-4-yl-6-(sulfoxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide
WO2022047790A1 (fr) * 2020-09-07 2022-03-10 Ningxia Academy Of Agriculture And Forestry Sciences Composés bicycliques substitués par amidine, leur préparation, leur utilisation comme agents antibactériens et inhibiteurs de bêta-lactamase
CN111943950B (zh) * 2020-09-10 2022-03-29 山东安信制药有限公司 一种瑞来巴坦的制备方法
US11814385B2 (en) 2021-06-25 2023-11-14 University Of South Florida Small molecule inhibitors targeting Clostridioides difficile sporulation
WO2023220324A1 (fr) * 2022-05-11 2023-11-16 The Regents Of The University Of Colorado A Body Corporate Composition antibiotique et ses procédés d'utilisation

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5071843A (en) 1978-07-24 1991-12-10 Merck & Co., Inc. Combination of 2-substituted carbapenems with dipeptidase inhibitors
US4880793A (en) 1978-07-24 1989-11-14 Merck & Co., Inc. Combination of thienamycin-type antibiotics with dipeptidase inhibitors
US4616038A (en) 1978-07-24 1986-10-07 Merck & Co., Inc. Combination of thienamycin-type antibiotics with dipeptidase inhibitors
US4539208A (en) 1980-09-17 1985-09-03 Merck & Co., Inc. Combination of thienamycin-type antibiotics with dipeptidase inhibitors
DK0508234T3 (da) 1991-04-11 1996-10-28 Hoffmann La Roche Beta-lactamer
CZ282567B6 (cs) 1993-12-29 1997-08-13 Pfizer Inc. Diazabicyklické sloučeniny a farmaceutické prostředky na jejich bázi
JP3199300B2 (ja) * 1994-05-09 2001-08-13 三共株式会社 １−メチルカルバペネム誘導体
ATE223411T1 (de) 1995-12-21 2002-09-15 Sankyo Co 1-methylcarbapenem-derivate
JP2965922B2 (ja) * 1995-12-21 1999-10-18 三共株式会社 １−メチルカルバペネム誘導体
JP2955276B2 (ja) * 1997-06-19 1999-10-04 三共株式会社 １−メチルカルバペネム誘導体を含有する抗菌剤
JP4490517B2 (ja) * 1998-03-19 2010-06-30 富山化学工業株式会社 ５−デオキシ−５−アルカノイルアミノ−β−Ｄ−アロフラノシルウロン酸誘導体またはその塩、それらを含有する抗真菌剤及びキチン合成酵素阻害剤
US6472406B1 (en) 1999-07-06 2002-10-29 Methylgene, Inc. Sulfonamidomethyl phosphonate inhibitors of beta-lactamase
CN1217932C (zh) * 1999-08-10 2005-09-07 英国生物技术药物有限公司 抗菌剂
FR2812635B1 (fr) 2000-08-01 2002-10-11 Aventis Pharma Sa Nouveaux composes heterocycliques, preparation et utilisation comme medicaments notamment comme anti- bacteriens
JP2002212182A (ja) * 2000-11-16 2002-07-31 Sankyo Co Ltd １−メチルカルバペネム誘導体
BR0115454A (pt) 2000-11-16 2003-09-23 Sankyo Co Composto de 1-metilcarbapenem ou um sal ou derivado de éster deste farmaceuticamente aceitável, composição farmacêutica, e, uso de um composto ou de um sal ou derivado de éster deste farmaceuticamente aceitável
FR2825705B1 (fr) 2001-06-08 2005-05-20 Aventis Pharma Sa Nouveaux composes heterocycliques, leur preparation et leur utilisation comme medicaments, notamment comme anti-bacteriens
FR2835186B1 (fr) * 2002-01-28 2006-10-20 Aventis Pharma Sa Nouveaux composes heterocycliques, actifs comme inhibiteurs de beta-lactamases
JP2004043438A (ja) * 2002-05-15 2004-02-12 Sankyo Co Ltd １−メチルカルバペネム誘導体を含有する医薬
US7439253B2 (en) 2002-12-06 2008-10-21 Novexel Heterocyclic compounds, their preparation and their use as medicaments, in particular as antibacterials and beta-lactamase inhibitors
EP2298323A3 (fr) * 2003-07-09 2011-05-11 Paratek Pharmaceuticals, Inc. Composés de tétracycline substitués
US6984652B2 (en) 2003-09-05 2006-01-10 Warner-Lambert Company Llc Gyrase inhibitors
JP2008502583A (ja) * 2003-10-01 2008-01-31 バイエル・ヘルスケア・アクチェンゲゼルシャフト 抗細菌性アミド大員環
EP1751527A2 (fr) 2004-02-24 2007-02-14 SSCI, Inc. Analyse et criblage de formes solides au moyen de la fonction de distribution de paires atomiques
CN103724330B (zh) 2005-12-07 2015-08-19 巴斯利尔药物股份公司 单环-内酰胺类抗生素与β-内酰胺酶抑制剂的有效的联合应用
US20100009957A1 (en) 2006-09-27 2010-01-14 Blizzard Timothy A Novel inhibitors of beta-lactamase
RS53052B (en) * 2008-01-18 2014-04-30 Merck Sharp & Dohme Corp. INHIBITOR BETA-LACTAMASE

Also Published As

Publication number Publication date
LTC2231667I2 (lt) 2021-07-26
JP2011207900A (ja) 2011-10-20
NO2020022I1 (no) 2020-08-10
SI2666774T1 (sl) 2015-04-30
NO2020024I1 (no) 2020-08-10
CN102827067A (zh) 2012-12-19
AU2009206119B2 (en) 2012-06-07
KR20100130176A (ko) 2010-12-10
HUS000504I2 (hu) 2021-03-29
AU2009206119C1 (en) 2016-05-26
MX2010007823A (es) 2010-08-10
CY2020025I2 (el) 2020-11-25
CY2020023I1 (el) 2020-11-25
DK2231667T3 (da) 2013-12-16
CR11626A (es) 2010-09-13
HUS2000024I1 (hu) 2021-03-29
MY162532A (en) 2017-06-15
IL206395A (en) 2015-04-30
ES2433744T3 (es) 2013-12-12
PL2666774T3 (pl) 2015-06-30
US20130274475A1 (en) 2013-10-17
CY1114900T1 (el) 2016-12-14
HN2010001395A (es) 2012-11-12
ES2533826T3 (es) 2015-04-15
ECSP10010568A (es) 2010-11-30
CA2712783A1 (fr) 2009-07-23
LTPA2020518I1 (lt) 2020-07-27
CY2020023I2 (el) 2020-11-25
SI2231667T1 (sl) 2013-12-31
US20110294777A1 (en) 2011-12-01
WO2009091856A3 (fr) 2009-12-03
JP5422020B2 (ja) 2014-02-19
LTC2666774I2 (lt) 2022-01-25
FR20C1032I1 (fr) 2020-02-10
RU2445314C9 (ru) 2013-04-10
BRPI0906871B1 (pt) 2021-09-28
BRPI0906871A2 (pt) 2020-07-28
EP2231667A2 (fr) 2010-09-29
FR20C1032I2 (fr) 2022-07-29
DOP2010000218A (es) 2010-08-31
AU2009206119A1 (en) 2009-07-23
KR101648728B1 (ko) 2016-08-17
NL301051I2 (nl) 2020-09-03
JP2011510012A (ja) 2011-03-31
CY2020024I1 (el) 2020-11-25
PT2666774E (pt) 2015-04-13
CN101918407A (zh) 2010-12-15
LTPA2020516I1 (lt) 2020-07-27
JP2012214475A (ja) 2012-11-08
HRP20150269T1 (hr) 2015-04-24
KR20160099117A (ko) 2016-08-19
FR20C1031I1 (fr) 2020-02-10
HUS000513I2 (hu) 2021-03-29
HK1143809A1 (en) 2011-01-14
EP2231667B1 (fr) 2013-09-04
DK2666774T3 (en) 2015-03-23
RS53052B (en) 2014-04-30
NO2020023I1 (no) 2020-08-10
CO6331438A2 (es) 2011-10-20
KR101800610B1 (ko) 2017-11-23
UA101966C2 (en) 2013-05-27
MA32025B1 (fr) 2011-01-03
CA2712783C (fr) 2013-03-19
FR20C1031I2 (fr) 2022-07-29
FR20C1030I1 (fr) 2020-02-10
LTPA2020517I1 (lt) 2020-07-27
HUS2000023I1 (hu) 2021-03-29
NZ586861A (en) 2011-12-22
EP2666774A1 (fr) 2013-11-27
ME02089B (fr) 2014-04-30
CY2020025I1 (el) 2020-11-25
PL2231667T3 (pl) 2014-01-31
US8487093B2 (en) 2013-07-16
CY2020024I2 (el) 2020-11-25
JP5038509B2 (ja) 2012-10-03
ZA201005333B (en) 2011-04-28
CN101918407B (zh) 2014-02-26
RS53862B1 (en) 2015-08-31
LUC00165I2 (fr) 2021-08-16
CN102827067B (zh) 2015-09-23
NL301050I2 (nl) 2020-09-03
HK1186180A1 (en) 2014-03-07
CY1116243T1 (el) 2017-03-15
NI201000115A (es) 2011-07-08
IL206395A0 (en) 2010-12-30
PT2231667E (pt) 2013-12-13
HRP20131123T1 (hr) 2013-12-20
JP5597164B2 (ja) 2014-10-01
EP2666774B1 (fr) 2015-01-07
WO2009091856A2 (fr) 2009-07-23
RU2445314C1 (ru) 2012-03-20
ECSP10010345A (es) 2010-08-31

Similar Documents

Publication Publication Date Title
FR20C1030I2 (fr) Inhibiteurs de beta-lactamase
CY2017016I2 (el) Αναστολεις πρωτεασωματος
BRPI0917808A2 (pt) inibidores de cmet
CR10831A (es) INHIBIDORES ESPIRO CETONA DE ACETIL-CoA CARBOXILASA
BRPI0807547A2 (pt) Inibidores de aspartil protease hetercíclicos
BRPI0810365A2 (pt) Inibidores de mlc-1 de indol 7-substituído
DK2041138T3 (da) Pyrroltriazinkinase-inhibitorer
DK2024375T3 (da) Cyclopropyl-kondenserede indolobenzazepin-HCV-NS5B-hæmmere
DK2340021T3 (da) Substituerede pyrrolidin-2-carboxamider
BRPI0806898A2 (pt) Inibidores de mek
BRPI0918564A2 (pt) inibidores
BRPI0814797A2 (pt) Inibidores dna-pk
DK2066662T3 (da) Serinhydrolaseinhibitorer
DK2240506T3 (da) IAP inhibitorer
AT507449A3 (de) Dämmstoffbefestiger
BRPI0918966A2 (pt) inibidores de protease
BRPI0912564A2 (pt) inibidores de jnk
ATE522533T1 (de) Pyrazolopyrimidinonkinaseinhibitor
BRPI0919073A2 (pt) inibidores de protease
FI20075320A0 (fi) Uusia käyttökelpoisia inhibiittoreita
BRPI0822880A2 (pt) alfa-mercapto-amidas
TH98069B (th) ที่วางของ
FI20080062A0 (fi) Työkalu
ATE529422T1 (de) 3-indazolyl-4-pyridylisothiazole